Literature DB >> 7359597

Hyperosmolality in the burn patient: analysis of an osmolal discrepancy.

M I Kulick, N S Lewis, V Bansal, R Warpeha.   

Abstract

In our study of 262 hospitalized flame burn patients, serum hyperosmolality, defined as having at least two reported osmolality values greater than 310 mOsm/kg, was observed in 15 patients (6%). From this group, nine patients were found to have an osmolal discrepancy (reported serum osmolality minus calculated serum osmolality). All patients in this group had a burn surface area greater than 35% TBS. The discrepancy between reported osmolality values of two patients from this group, determined by freezing point depression and vapor point analysis, suggested that a volatile substance was contributing to the osmolality. Further analysis by gas chromatography revealed propylene glycol as the agent accounting for most of the osmolal discrepancy. The only exposure to this polyalcohol was from the topical antibiotic cream (silver sulfadiazine) used in their treatment.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7359597

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  4 in total

Review 1.  Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).

Authors:  L K Golightly; S S Smolinske; M L Bennett; E W Sutherland; B H Rumack
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 May-Jun

2.  Persistent lactic acidosis after chronic topical application of silver sulfadiazine in a pediatric burn patient: a review of the literature.

Authors:  Monte S Willis; Bruce A Cairns; Ashley Purdy; Andrey V Bortsov; Samuel W Jones; Shiara M Ortiz-Pujols; Tina M Schade Willis; Benny L Joyner
Journal:  Int J Burns Trauma       Date:  2013-01-24

3.  Pharmacokinetics of propylene glycol after rectal administration.

Authors:  W J Kollöffel; L E Weekers; P B Goldhoorn
Journal:  Pharm World Sci       Date:  1996-06

4.  Propylene glycol-induced side effects during intravenous nitroglycerin therapy.

Authors:  H E Demey; R A Daelemans; G A Verpooten; M E De Broe; C M Van Campenhout; F V Lakiere; P J Schepens; L L Bossaert
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.